Study of CAD-1883 for Spinocerebellar Ataxia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.
Epistemonikos ID: ebf2e4c84e34361e5b08d5c54ee428cc3e9d10ae
First added on: May 07, 2024